---
title: "CICC: CSPC PHARMA  3Q Results In Line, Core Business Remains Solid"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306221587.md"
description: "CICC released a research report on CSPC PHARMA's Q3 results, noting they were in line with expectations. Revenue rose 0.72% YoY to RMB6.665 billion, while core net profit surged 39.04% to RMB1.055 billion, driven by strong performance in nervous system and digestive metabolism segments. However, CICC lowered 2026 and 2027 net profit forecasts by 8.4% and 5.4% respectively due to deferred out-licensing income recognition. The broker maintained an 'Outperform' rating with a target price of HKD12."
datetime: "2026-11-20T05:26:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306221587.md)
  - [en](https://longbridge.com/en/news/306221587.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306221587.md)
generator: "portal-rs"
---

# CICC: CSPC PHARMA  3Q Results In Line, Core Business Remains Solid

CICC published a research report stating that CSPC PHARMA (01093.HK) -0.325 (-3.916%) Short selling $86.04M; Ratio 34.089% announced its third-quarter results, with revenue of RMB6.665 billion, up 0.72% YoY; net profit attributable to shareholders reached RMB982 million, up 1.94% YoY; core net profit was RMB1.055 billion, up 39.04% YoY. Core business performance was in line with market expectations.

The broker noted that the core finished drug business remained solid, with the nervous system and digestive metabolism segments driving growth. Third-quarter revenue from the nervous system segment was RMB2.528 billion, up 32.1% YoY; digestive metabolism revenue was RMB351 million, up 41.4% YoY; anti-infective revenue was RMB844 million, up 2.3% YoY; oncology revenue was RMB461 million, down 22.5% YoY; and cardiovascular revenue was RMB404 million, down 14.7% YoY.

Third-quarter gross margin was 66.6%, up 1.0 ppts YoY. The selling expense ratio was 24.4%, down 2.0 ppts YoY, while the R&D expense ratio was 24.2%. Licensing income for the first three quarters amounted to RMB6.268 billion, including RMB5.74 billion recognized as the upfront payment from the long-acting peptide cooperation with AstraZeneca, while the remaining RMB2.425 billion has yet to be recognized.

Considering the deferred recognition of out-licensing income, the broker lowered CSPC PHARMA's 2026 and 2027 net profit forecasts by 8.4% and 5.4% respectively, to RMB8.665 billion and RMB5.271 billion. It maintained an "Outperform" rating and a TP of HKD12, corresponding to 2026 and 2027 P/E ratios of 13.8x and 21.9x respectively. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 12:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [03908.HK](https://longbridge.com/en/quote/03908.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [CSPC Starts Phase II Trial of New RSV Drug SYH2066 in China](https://longbridge.com/en/news/302701865.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**